MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

The management of Parkinson’s disease in the Middle East countries: the MDS-middle east task force survey

H. Khalil, Z. Aldaajani, S. Baudry, M. Abualmelh, T. Mohammad, M. Salari, M. Bhatt, S. Tabbal, N.A. Syed, B. Jeon, C. Goetz, J.A. Bajwa (Irbid, Jordan)

Meeting: 2017 International Congress

Abstract Number: 1296

Keywords: Parkinsonism

Session Information

Date: Thursday, June 8, 2017

Session Title: Other

Session Time: 1:15pm-2:45pm

Location: Exhibit Hall C

Objective: The movement disorders society task force for the Middle East (MDS-Task Force for the Middle East) conducted a survey with an aim of characterizing the needs, the challenges and the limitations for providing care for people with Parkinson’s disease in the region

Background: Middle East includes numerous developing countries with an estimated population of over 500 million. The prevalence of PD in the region is believed to be similar to the prevalence reported worldwide. The fields of PD and movement disorders are however underdeveloped and underserved in the region.

Methods: Asurvey was specifically developed for the purposes of this study by MDS-Task Force for the Middle East. It was distributed electronically to the MDS members from the middle east countries (n= 226). Members were from Afghanistan, Bahrain, Iran, Iraq, India, Jordan, Kazakhstan, Kuwait, Lebanon, Pakistan, Palestine Territory, Saudi Arabia, UAE and Uzbekistan. The survey wasintended  to elicit information about available treatments and facilities, needs, challenges and limitation for managing PD in responders’ countries. 

Results: Fifty two members from seven different countries responded to the survey. Responders were from Iran, Iraq, Jordan, Kuwait, Lebanon, Pakistan, Saudi Arabia, UAE and Uzbekistan. Most responders indicated that a centre of excellence for PD does not exist in their countries (75%) nor a rehab centre for PD (80%). Levodopa combinations, amantadine and donepezil were indicated to be available and affordable by the vast majority of the responders. Neurosurgical options or infusion therapies for treating advanced PD were indicated to lack by the vast majority of the responders (90-94%). The scarce of the movement disorders’ specialists, educational opportunities, research, as well as the high cost of treatment, the lack of general health infrastructure, resources and health insurance coverage were described as the main barriers to provide care for people with PD in the Middle East countries. 

Conclusions: This is the first survey that sheds the light into the unmet needs in providing care for people with PD in the Middle East countries. The data suggests that there is a great need to increase the awareness of PD and provide educational opportunities within this field in the Middle East countries.

To cite this abstract in AMA style:

H. Khalil, Z. Aldaajani, S. Baudry, M. Abualmelh, T. Mohammad, M. Salari, M. Bhatt, S. Tabbal, N.A. Syed, B. Jeon, C. Goetz, J.A. Bajwa. The management of Parkinson’s disease in the Middle East countries: the MDS-middle east task force survey [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/the-management-of-parkinsons-disease-in-the-middle-east-countries-the-mds-middle-east-task-force-survey/. Accessed May 9, 2025.
  • Tweet
  • Email
  • Print

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-management-of-parkinsons-disease-in-the-middle-east-countries-the-mds-middle-east-task-force-survey/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley